UBS/CALL/ROCHE GS/400.004/0.025/20.12.24 Stock

Warrant

AROGSU

CH1111510025

Market Closed - Swiss Exchange 11:20:00 2024-05-16 EDT
0.004 CHF +100.00% Intraday chart for UBS/CALL/ROCHE GS/400.004/0.025/20.12.24
Current year-84.62%

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
AROGSU
ISINCH1111510025
Date issued 2021-08-11
Strike 400 CHF
Maturity 2024-12-20 (207 Days)
Parity 40 : 1
Emission price 0.77 CHF
Emission volume N/A
Settlement physical
Currency CHF

Technical Indicators

Highest since issue 1.067 CHF
Lowest since issue 0.002 CHF
Spread 0.026 CHF
Spread %92.86%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
229.9 CHF
Average target price
279.8 CHF
Spread / Average Target
+21.72%
Consensus
  1. Stock Market
  2. Warrants
  3. AROGSU Warrant